AR007747A1 - Inhibidores del reflujo - Google Patents

Inhibidores del reflujo

Info

Publication number
AR007747A1
AR007747A1 ARP970104051A ARP970104051A AR007747A1 AR 007747 A1 AR007747 A1 AR 007747A1 AR P970104051 A ARP970104051 A AR P970104051A AR P970104051 A ARP970104051 A AR P970104051A AR 007747 A1 AR007747 A1 AR 007747A1
Authority
AR
Argentina
Prior art keywords
reflux inhibitors
reflux
inhibitors
gaba
inhibition
Prior art date
Application number
ARP970104051A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR007747(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR007747A1 publication Critical patent/AR007747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Se relaciona con el uso de agonistas de los receptores GABA (B) para la inhibición de las relajaciones transitorias del esfínter esofágico inferior, ypara el tratamiento de la enfermedad de reflujo gastroesofágico.
ARP970104051A 1996-09-18 1997-09-04 Inhibidores del reflujo AR007747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use

Publications (1)

Publication Number Publication Date
AR007747A1 true AR007747A1 (es) 1999-11-10

Family

ID=20403936

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104051A AR007747A1 (es) 1996-09-18 1997-09-04 Inhibidores del reflujo

Country Status (34)

Country Link
US (2) US6117908A (es)
EP (2) EP0936906B1 (es)
JP (1) JP4098832B2 (es)
KR (2) KR100568659B1 (es)
CN (1) CN1117560C (es)
AR (1) AR007747A1 (es)
AT (2) ATE249212T1 (es)
AU (1) AU714370B2 (es)
BR (1) BR9711400A (es)
CA (1) CA2265615C (es)
CZ (1) CZ299997B6 (es)
DE (2) DE69724809T2 (es)
DK (2) DK1344524T3 (es)
EE (1) EE03952B1 (es)
ES (2) ES2206749T3 (es)
HU (1) HU224968B1 (es)
ID (1) ID19621A (es)
IL (1) IL128961A (es)
IS (2) IS2329B (es)
MY (1) MY122020A (es)
NO (1) NO326837B1 (es)
NZ (2) NZ504244A (es)
PL (1) PL190028B1 (es)
PT (2) PT936906E (es)
RU (1) RU2199316C2 (es)
SA (1) SA97180522B1 (es)
SE (1) SE9603408D0 (es)
SI (2) SI1344524T1 (es)
SK (1) SK285744B6 (es)
TR (1) TR199900591T2 (es)
TW (1) TW548104B (es)
UA (1) UA61081C2 (es)
WO (1) WO1998011885A1 (es)
ZA (1) ZA977969B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease
MXPA03011096A (es) * 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
SE0102058D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
AR033779A1 (es) 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0102055D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Compounds
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
ATE546427T1 (de) * 2003-08-20 2012-03-15 Xenoport Inc Acyloxyalkylcarbamat-prodrugs, syntheseverfahren und anwendung
AU2004272302A1 (en) * 2003-09-12 2005-03-24 Janssen Pharmaceutica N.V. Chimeric GABAb receptor
WO2005037784A2 (en) * 2003-10-14 2005-04-28 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
GB0327186D0 (en) * 2003-11-21 2003-12-24 Novartis Ag Organic compounds
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
BRPI0620345A2 (pt) * 2005-12-23 2017-11-21 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, métodod para o tratamento de uma doença
JP2009521427A (ja) * 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ 胃食道逆流症及び過敏性腸症候群の治療のためのピラゾール
EP1968946A4 (en) * 2005-12-23 2010-05-05 Astrazeneca Ab IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR
BRPI0620464A2 (pt) * 2005-12-23 2011-11-16 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
US7745474B2 (en) 2005-12-23 2010-06-29 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
NZ598728A (en) * 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
KR20100015648A (ko) * 2007-04-18 2010-02-12 아스트라제네카 아베 양성 알로스테릭 ｇａｂａｂ 수용체 조절제 효과를 갖는 크산틴 화합물
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
JP2010534239A (ja) * 2007-07-25 2010-11-04 アストラゼネカ・アクチエボラーグ Ｎｅｒｄの治療のための（３−アミノ−２−フルオロプロピル）ホスフィン酸の使用
TW200936123A (en) * 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
JP5563483B2 (ja) * 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US8993639B2 (en) * 2008-03-20 2015-03-31 Burt Shulman Compound and method for treatment of gastroesophageal reflux
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
CA2753057C (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
WO2010120370A2 (en) * 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
EP2854774A4 (en) 2012-06-01 2015-11-18 Lynn Health Science Inst Inc METHODS OF TREATING INSOMNIA
US12161695B2 (en) * 2018-02-22 2024-12-10 Diamyd Medical Ab GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells
TW202412754A (zh) * 2022-06-07 2024-04-01 瑞士商意梭凱普公司 應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594424B2 (en) * 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
NO882881L (no) * 1988-06-29 1990-01-02 Trond Nilsen Anordning for lengdekorrugering av metallplater.
GB8820266D0 (en) * 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
AU5106790A (en) * 1989-02-03 1990-09-05 Cambridge Neuroscience Research, Inc. Method of screening and classifying compounds
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
EP0713698B1 (en) * 1992-01-22 2002-04-03 Glaxo Group Limited Medical use of atypical beta-adrenoceptor agonists
GB9408064D0 (en) * 1994-04-22 1994-06-15 Merck Sharp & Dohme Nucleic acids
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions

Also Published As

Publication number Publication date
IL128961A0 (en) 2000-02-17
HUP9903825A2 (hu) 2001-05-28
ID19621A (id) 1998-07-23
SK30599A3 (en) 2000-01-18
IS2329B (is) 2008-01-15
NZ334495A (en) 2000-09-29
EP1344524B1 (en) 2006-08-02
BR9711400A (pt) 1999-08-17
ZA977969B (en) 1998-03-18
EP0936906B1 (en) 2003-09-10
HUP9903825A3 (en) 2001-06-28
IS2538B (is) 2009-09-15
DE69736445T2 (de) 2007-03-15
MY122020A (en) 2006-03-31
CZ93099A3 (cs) 1999-09-15
TR199900591T2 (xx) 1999-07-21
RU2199316C2 (ru) 2003-02-27
HK1022100A1 (en) 2000-07-28
IS5001A (is) 1999-03-15
NO326837B1 (no) 2009-02-23
CA2265615C (en) 2007-01-30
SA97180522B1 (ar) 2006-04-04
PT1344524E (pt) 2006-11-30
EE9900095A (et) 1999-10-15
KR20050101237A (ko) 2005-10-20
EP0936906A1 (en) 1999-08-25
US6664069B1 (en) 2003-12-16
EE03952B1 (et) 2003-02-17
PL190028B1 (pl) 2005-10-31
NZ504244A (en) 2000-09-29
PL332497A1 (en) 1999-09-13
AU4406497A (en) 1998-04-14
SI0936906T1 (en) 2004-02-29
PT936906E (pt) 2003-12-31
HU224968B1 (en) 2006-04-28
CN1117560C (zh) 2003-08-13
IS8623A (is) 2007-03-19
SE9603408D0 (sv) 1996-09-18
DE69724809T2 (de) 2004-07-15
JP4098832B2 (ja) 2008-06-11
ES2206749T3 (es) 2004-05-16
ES2268227T3 (es) 2007-03-16
WO1998011885A1 (en) 1998-03-26
ATE334700T1 (de) 2006-08-15
KR100553294B1 (ko) 2006-02-22
NO991287L (no) 1999-03-17
DK0936906T3 (da) 2003-11-24
IL128961A (en) 2004-08-31
SK285744B6 (sk) 2007-07-06
EP1344524A1 (en) 2003-09-17
KR100568659B1 (ko) 2006-04-07
UA61081C2 (uk) 2003-11-17
JP2001501604A (ja) 2001-02-06
DE69736445D1 (de) 2006-09-14
NO991287D0 (no) 1999-03-17
KR20000036185A (ko) 2000-06-26
DE69724809D1 (de) 2003-10-16
CN1237105A (zh) 1999-12-01
SI1344524T1 (sl) 2006-12-31
CZ299997B6 (cs) 2009-01-14
CA2265615A1 (en) 1998-03-26
HK1057004A1 (en) 2004-03-12
AU714370B2 (en) 1999-12-23
US6117908A (en) 2000-09-12
ATE249212T1 (de) 2003-09-15
TW548104B (en) 2003-08-21
DK1344524T3 (da) 2006-10-30

Similar Documents

Publication Publication Date Title
AR007747A1 (es) Inhibidores del reflujo
EA200300105A1 (ru) Нестероидные ингибиторы воспалений
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
EA200200208A1 (ru) Синергитическая композиция
CU23029A3 (es) Analogos sustituidos del benzopirano para el tratamiento de la inflamacion
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR023777A1 (es) Nuevos compuestos
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2172579T3 (es) Agonistas/antagonistas de estrogenos.
DE69916792D1 (de) Kaliumkanalblocker
ATE250571T1 (de) Kaliumkanal-blocker
CL2004000655A1 (es) Compuestos derivados de piperidin-2-ona 1,6-disustituidos, sus sales, composicion farmaceutica, agonistas del receptor ep4; uso de los compuestos para tratar hipertension ocular, glaucoma.
ES2319886T3 (es) Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
EA200001222A1 (ru) Производные аденозина
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
CL2007001176A1 (es) Compuestos derivados de piridina-triazol-pirrolidina, moduladores del receptor de glutamato metabotropico (mglur5); composiciones farmaceuticas que los contienen; combinacion de ellos con un agente inhibidor de la secrecion acida; intermediarios; y su uso trastornos neurologicos,psiquiatricos, gastrointestinales y otros.
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
BR0011801A (pt) Inibidores de benzamida substituìda para 3c protease de rinovìrus
BR0112355A (pt) Uso de inibidores da proteìna egf-r tirosina cinase para a prevenção do fotoenvelhecimento da pele humana
DE60118560D1 (de) Nicht-nukleosid reverse transkriptase inhibitoren
ECSP034604A (es) Inhibicion de la dependendia de celulas tumorales del factor de crecimiento
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada

Legal Events

Date Code Title Description
FB Suspension of granting procedure